Industry leader in the development of enterprise-wide computer-aided detection (CAD) software expands product registration with clinivation’s global CRO services.
Framingham, MA, July 19, 2007 – clinivation, Inc. announced today that Medicsight PLC (London: MDST) has selected clinivation’s Approvals solution. “Medicsight is clearly an industry leader in medical imaging software solutions, delivering CAD and other imaging products for the earlier detection of disease,” said Joseph Kozikowski, M.D., clinivation’s President and Chief Executive Officer. “We are pleased that Medicsight’s senior management has selected clinivation to help position their products for continued growth and expansion,” he continued.
Clinivation’s global CRO Services delivers regulatory expertise, development strategy, and an outstanding track record.
About Medicsight:
Medicsight PLC is a leading developer of computer-aided detection (CAD) technologies and image analysis software. Medicsight PLC’s software solutions help clinicians identify, measure and analyse suspicious pathology such as colorectal polyps and lung lesions on CT scans. The patent protected CAD technology developed by Medicsight PLC is validated against one of the world’s largest and most population diverse databases of verified CT scan data. The company’s products include ColonCAD™ and ColonCAR™, and LungCAD™ and LungCAR™. These products seamlessly integrate with the advanced 3D visualisation platforms of industry leading partners. Medicsight is committed to the ongoing development of innovative global solutions for improving clinician workflow to support the detection, interpretation and diagnosis of disease at the earliest possible stage.
